	Application No.	Applicant(s)	
Notice of Allowability			
	09/825,561 Examiner	SPRECHER Art Unit	
nones of fundamity	LAGIIIIIGI		
	Ruixiang Li	1646	
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT Report of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED or other appropriate comm GHTS. This application is	in this application. If not included nunication will be mailed in due course.	THIS initiative
1. ☐ This communication is responsive to <u>3/15/2004</u> .			
2. The allowed claim(s) is/are 37, 48-51, 61-72, & 74-84, which are renumbered as 1, 5-7, 2, 9-19, 21-23, 8, 20, 24, 3, 4, and 25-28, respectively.			
3. The drawings filed on are accepted by the Examine	r.		
 4. ☐ Acknowledgment is made of a claim for foreign priority ureal. a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 	been received.		
3. Copies of the certified copies of the priority do			n the
International Bureau (PCT Rule 17.2(a)).		3	
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		e a reply complying with the requiremen	nts
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
6. CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftspers		w (PTO-948) attached	
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date	•		
(b) including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment o	or in the Office action of	
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on he header according to 37 C	the drawings in the front (not the back) of FR 1.121(d).	f
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/O Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit	6. ☐ Interview S Paper No 7. ☑ Examiner's	nformal Patent Application (PTO-152) Summary (PTO-413), ./Mail Date s Amendment/Comment s Statement of Reasons for Allowance	
of Biological Material	9. ☐ Other		
-			

Art Unit: 1646

EXAMINER'S AMENDMENT

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes

and/or additions be unacceptable to applicant, an amendment may be filed as provided

by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be

submitted no later than the payment of the issue fee. Authorization for this examiner's

amendment was given in a telephone interview with Jennifer K. Johnson on March 17,

2004.

Amendment to claim 37:

At the end of line 2 of claim 37, please insert the word "two" after "comprising".

Examiner's Statement of Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The present invention discloses an isolated heterodimeric or multimeric soluble receptor

complex comprising (i) a soluble receptor subunit that comprises a soluble receptor

polypeptide comprising the amino acid sequence of SEQ ID NO: 6 and (ii) a soluble

receptor subunit that comprises a soluble receptor polypeptide comprising soluble IL-2

Art Unit: 1646

Ry receptor polypeptide (SEQ ID NO: 4). The claimed invention is enabled and is not

Page 3

anticipated or suggested by the prior art.

Presnell et al. (U.S. Patent No. 6,576,744 B1, June 10, 2003) teach a class I cytokine

receptor comprising the amino acid sequence of SEQ ID NO: 6, which is the same as

Zalpha11 cytokine receptor of the present invention (Abstract; top of column 10).

Presnell et al. further teach that the Zalpha11 cytokine receptor polypeptide may be

multimers (line 11 of column 36), or form a heterodimer with the interleukin 4 (IL-4)

cytokine receptor alpha-subunit (lines 16-19 of column 46). However, Presnell et al. do

not teach that the Zalpha11 cytokine receptor polypeptide forms a heterodimeric or

multimeric complex with a soluble IL-2 Ry receptor polypeptide (SEQ ID NO: 4). Thus,

the reference of Presnell et al. does not anticipate or suggest the present invention in its

entirety.

Any comments considered necessary by applicant must be submitted no later than the

payment of the issue fee and, to avoid processing delays, should preferably accompany

the issue fee. Such submissions should be clearly labeled "Comments on Statement of

Reasons for Allowance."

Conclusion

Claims 37, 48-51, 61-72, and 74-84 are allowed. They are renumbered as 1, 5-7, 2, 9-

19, 21-23, 8, 20, 24, 3, 4, and 25-28, respectively.

Application/Control Number: 09/825,561

Art Unit: 1646

Advisory Information

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875.

The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00

pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Yvonne Eyler, can be reached on (571) 272-0871. The fax number for this

Group is (703) 872-9306.

Communications via Internet e-mail regarding this application, other than those under

35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and

should be addressed to [yvonne.eyler@uspto.gov]. All Internet e-mail

communications will be made of record in the application file. PTO employees do not

engage in Internet communications where there exists a possibility that sensitive

information could be identified or exchanged unless the record includes a properly

signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is

more clearly set forth in the Interim Internet Usage Policy published in the Official

Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Ruixiang Li Examiner March 17, 2004

GARY KUNZ SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

Page 4